Gene Therapy

Hemophilia A Gene Therapy- Key opinion leaders (KOLs) Insight- An Executive Report 2020 Deck provides a competitive advantage towards understanding the current gene therapy challenges, safety and efficacy concerns, hemophilia A gene therapy market uptake, Gene therapy competition, Hem A gene therapy re-dosing, Patients switching to gene therapy from hemlibra and factor replacement therapies and other critical key intelligent questions through 14 in-depth interviews with leading US and European KOLs.